Top Injectable Manufacturer in the Bahamas - Reliable Pharmaceutical Solutions
Why Farbe Firma is the Leading Injectable Manufacturer in the Bahamas
Last Updated: 15 September 2026
TL;DR: The Bahamas has no product registration or marketing authorisation regime for medicines. The Pharmacy Act, 2009, consolidated as Chapter 227, runs to 52 sections and creates no drug register and no dossier assessment. What it creates instead is a pharmacopoeia standard and a premises-and-person licensing system run by the Bahamas Pharmacy Council. The Bahamas National Drug Agency is a procurement unit of the Public Hospitals Authority, not a regulator. Farbe Firma Pvt Ltd manufactures over 100 sterile injectables under WHO-GMP in ISO Class 5 cleanrooms in Gujarat, India, releases to USP and BP specifications, and supplies more than 30 countries.
Key Takeaways
There is no Bahamian marketing authorisation to obtain. The Pharmacy Act Chapter 227 contains no register of medicinal products, and the Pharmacy Council's published fee schedule contains no product registration fee of any kind, which corroborates the absence rather than merely asserting it.
Section 27(1) is the real list, and it names pharmacopoeias rather than authorities: the British, United States, European and International Pharmacopoeias, plus any other approved by the Minister. The Indian Pharmacopoeia is not among the four named, and no instrument adding it was found.
The practical gate is a Bahamian counterparty: a Pharmacy Council registered warehouse and a wholesale distributor licence, each valid one year, with import and export governed by the Customs Management Act.
The lists that do exclude India belong to CARPHA's Caribbean Regulatory System and to PAHO-funded procurement, not to Bahamian law. CDSCO appears on neither, and its WHO transitional listing is scoped to vaccines rather than medicines.
Introduction: What an Injectable Manufacturer in the Bahamas Actually Has to Clear
The Bahamas is a high-income market of 403,033 people on World Bank 2025 data, with GNI per capita of USD 37,020 in 2024 and current health expenditure of USD 2,262 per capita, 6.3 percent of GDP, in 2023. Out-of-pocket spending is 27.5 percent and life expectancy is 74.7 years in 2024. Non-communicable disease carried 73.1 percent of total deaths in 2019, with a 20.3 percent probability of premature death between ages 30 and 70. There is no domestic manufacturing base to displace. Competition is on price, reliability and shipping rather than on dossiers.
That last point is not a figure of speech. The governing statute is the Pharmacy Act, 2009, Act No. 8 of 2009, consolidated as Chapter 227 and most recently republished as the LRO 1/2017 edition. Its Arrangement of Sections runs from section 1 to section 52 and covers the Pharmacy Council, registration of pharmacies, registration and licensing of pharmacists and technicians, discipline, the sale and administration of drugs, the standard and importation of drugs, poisons, prescriptions, registration of factories and warehouses, and licensing of manufacturers and wholesalers. Nowhere in it is there a register of medicinal products, a marketing authorisation, or a dossier assessment. A Pharmacy (Amendment) Act 2013 exists, but the government PDF returned no machine-readable text, so we do not describe what it changed.
What Sets a World-Class Injectable Manufacturer in the Bahamas Apart
Where there is no dossier to file, the differentiator moves to the specification and the counterparty. Section 27(1) requires every drug manufactured, offered for sale, imported or exported to meet one of the British Pharmacopoeia, the United States Pharmacopoeia, the European Pharmacopoeia, the International Pharmacopoeia, or any other pharmacopoeia approved by the Minister, with breach an offence carrying a fine of up to twenty thousand dollars. The Indian Pharmacopoeia is not among the four named. It could in principle enter through the Ministerial limb, but no instrument doing so was found, and no comprehensive index of orders made under the Act was located, so the position is not-found rather than proven-absent.
This is a soft constraint for a manufacturer that plans for it, and a hard one for a manufacturer that does not. Farbe Firma releases to USP and BP specifications as a matter of routine, which satisfies section 27 directly and removes the question. The second half of the gate is sections 33 to 36: no person may import drugs for storage and wholesale distribution unless the warehouse is registered with the Bahamas Pharmacy Council, with penalties up to fifteen thousand dollars, and the Council separately licenses manufacturers and wholesale distributors. Both the premises certificate and the licence are valid for one year. The Council's published Second Schedule sets warehouse registration at 2,000 dollars with renewal at 1,000, and a wholesale distributor licence at 500 with renewal at 250. Import and export themselves are governed by the Customs Management Act.
Quality Systems Behind Every Batch Shipped to the Bahamas
Farbe Firma manufactures more than 100 sterile injectables at a WHO-GMP certified facility in Gujarat, India, with aseptic filling in ISO Class 5 environments and supply into more than 30 countries. The same quality system that supports our CTD and ACTD dossiers in registration markets supports a Bahamian consignment where no dossier is filed: validated aseptic process simulations, routine environmental monitoring, HPLC and GC assay and related-substance methods, Karl Fischer moisture determination, LAL bacterial endotoxin testing, container closure integrity testing, and ICH Q1A stability programmes with photostability under ICH Q1B.
Stability deserves a precise statement rather than a confident one. WHO's stability-conditions table, in its March 2021 update, carries the Bahamas at 30 degrees Celsius and 65 percent relative humidity. The entry is bracketed and footnoted, which in WHO's own key means it was supplied by the IFPMA from climate literature rather than confirmed by a Bahamian regulator, and WHO states a condition rather than a zone label. India's own entry in the same table is 30 degrees Celsius and 70 percent relative humidity and is marked as officially confirmed. Indian long-term data therefore meets or exceeds the condition attributed to the Bahamas, which is a useful fact and one we are careful not to overstate into a Bahamian requirement that no Bahamian instrument has ever set.
Why Farbe Firma is the Trusted Injectable Manufacturer in the Bahamas for Global Buyers
The absence of a registration regime is an opportunity and a discipline at the same time. There is no dossier moat protecting an incumbent, so a new supplier can move quickly. But there is also no regulatory review standing between a buyer and a bad batch, which means the buyer's own diligence carries the whole load. That is precisely the situation in which a WHO-GMP certificate, a genuine ISO Class 5 aseptic operation, batch-level certificates of analysis and an auditable stability file stop being paperwork and start being the entire basis of trust. We would rather be bought on that basis than on price alone.
It is equally important to be honest about what an Indian file cannot reach. CARPHA's Caribbean Regulatory System is reliance-gated: it recommends only products already authorised by a listed reference authority, or WHO-prequalified, and CDSCO appears on no such list. PAHO-funded procurement applies the same test, admitting WHO Prequalification, stringent regulatory authorities or the Americas-only national authorities of regional reference. CDSCO's WHO transitional listing, in the December 2025 version, is scoped to vaccines and not to medicines. Neither the Bahamas nor India appears on any of the four PIC/S lists, including former pre-applicants. And India's own bilateral record for the Bahamas names four instruments, on foreign office consultations, bilateral cooperation, tax information exchange and visa exemption, with nothing on pharmaceuticals, GMP recognition or pharmacopoeia recognition. The Indian Pharmacopoeia Commission's own recognition list, updated 10 July 2026, names twenty-five countries including nine in the Caribbean and Latin America; the Bahamas is not among them.
Two structural facts frame the commercial reading. The Bahamas is a full CARICOM member but does not participate in the CARICOM Single Market and Economy, and it is a World Trade Organization observer rather than a member, with an accession pending since 2001 and resumed in 2017. Neither fact blocks supply, but both mean regional shortcuts arrive here later than elsewhere, and that the practical route runs through a licensed Bahamian wholesaler and, for public volume, through tender. That is the route we build with partners: correct pharmacopoeial specification, a licensed counterparty with a registered warehouse, English labelling, and a stability file that already exceeds the condition WHO attributes to the islands.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Do I need to register a medicine in the Bahamas before importing it?
No Bahamian product registration or marketing authorisation was found. The Pharmacy Act Chapter 227 creates no drug register and no dossier assessment, and the Pharmacy Council's fee schedule contains no product registration fee. What is required is that the product meets a section 27 pharmacopoeia and that the importer holds a Council registered warehouse and a wholesale distributor licence. We state this as no such regime found rather than as a regime confirmed absent by the regulator.
Does the Bahamas National Drug Agency approve medicines?
No, and this is the most common error made about the Bahamian system. The BNDA was formed in 1994 to streamline purchasing for public sector health facilities and now sits under the Public Hospitals Authority as a shared service unit. Its listed functions are supply management and tendering, pharmacy policy, training and narcotic records. No marketing authorisation, dossier assessment, GMP inspection or pharmacovigilance function is listed. It is also a different body from the Bahamas National Drug Council, which works on substance abuse.
Is the Indian Pharmacopoeia accepted in the Bahamas?
Not among the four pharmacopoeias named in section 27(1), which are the British, United States, European and International Pharmacopoeias. Section 27(1)(v) allows the Minister to approve another pharmacopoeia, but no instrument doing so was found and no comprehensive index of orders under the Act was located. In practice this is straightforward to work around: Farbe Firma releases to USP and BP specifications, which satisfies section 27 directly.
How does an Indian supplier reach public-sector volume in the Bahamas?
Through tender rather than registration. The BNDA's remit expressly includes tendering exercises for the public hospitals. Separately, the National Health Insurance (Specified Chronic Diseases) (Prescription Drug Fund) Act 2025 was assented and gazetted on 28 August 2025 and would move the national prescription drug plan from the National Insurance Board to the National Health Insurance Authority, allowing contracts with international suppliers under the Public Procurement Act 2023. Its section 1(2) provides for commencement on a date appointed by the Minister, and we could not confirm that the notice has issued, so this should be treated as pending rather than in force. We did not locate a current tender portal or supplier prequalification document and make no claim about how to register as a supplier.
Does a CARPHA or PAHO route help an Indian injectable manufacturer here?
Not on a CDSCO-only file. CARPHA's Caribbean Regulatory System issues recommendations rather than authorisations and accepts only products already authorised by a listed reference authority or WHO-prequalified; CDSCO is on neither list and WHO-GMP is not an eligibility route. PAHO-funded procurement applies the same reliance test. WHO's April 2022 account describes technical support to establish a Bahamian fast approval pathway recognising CRS recommendations in the future tense, and we found no instrument completing it in the years since, so we treat it as an open watch item rather than an available route.
Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India.
Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. Email director@farbefirma.org. Request a Quote / View Products / Blog
Comments